Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: Results from the randomized phase III ESTIMABL trial

Journal of Clinical Oncology

Volumn 33, Issue 26, 2015, Pages 2885-2892

  Borget, Isabelle ^a,b,c   Bonastre, Julia ^a,b   Catargi, Bogdan ^f   Déandréis, Désirée ^a   Zerdoud, Slimane ^h   Rusu, Daniela ^j   Bardet, Stéphane ^k   Leenhardt, Laurence ^d   Bastie, Delphine ⁱ   Schvartz, Claire ^l   Vera, Pierre ^m   Morel, Olivier ⁿ   Benisvy, Daniele ^o   Bournaud, Claire ^p   Bonichon, Francoise ^g   Kelly, Antony ^q   Toubert, Marie Elisabeth ^e   Leboulleux, Sophie ^a   Journeau, Florence ^a   Benhamou, Ellen ^a,b   Schlumberger, Martin ^a,c   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g INSTITUT BERGONIÉ   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k CENTRE FRANÇOIS BACLESSE   (France)

^l INSTITUT JEAN GODINOT   (France)

^m Centre Becquerel   (France)

ⁿ UMR INSERM U892 CNRS 6299   (France)

^o Centre Lacassagne   (France)

^p HOSPICES CIVILS DE LYON   (France)

^q CENTRE JEAN PERRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN;

ABLATION THERAPY; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LEAVE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; THYROID CANCER; THYROIDECTOMY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; HEALTH CARE PLANNING; PSYCHOLOGY; QUALITY OF LIFE; THYROID NEOPLASMS;

COST-BENEFIT ANALYSIS; HEALTH RESOURCES; HUMANS; IODINE RADIOISOTOPES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 84952984600     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6722     Document Type: Article

References (30)

1. Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306, 1998
2. Pacini F, Schlumberger M, Dralle H, et al: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803, 2006
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214, 2009
4. Pacini F, Ladenson PW, Schlumberger M, et al: Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932, 2006
5. Schlumberger M, Catargi B, Borget I, et al: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 366:1663-1673, 2012
6. Mallick U, Harmer C, Yap B, et al: Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 366:1674-1685, 2012
7. Schroeder PR, Haugen BR, Pacini F, et al: A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878-884, 2006
8. Luster M, Felbinger R, Dietlein M, et al: Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: A one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15:1147-1155, 2005
9. Lee J, Yun MJ, Nam KH, et al: Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173-179, 2010
10. Borget I, Remy H, Chevalier J, et al: Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: Comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457-1463, 2008
11. Borget I, Corone C, Nocaudie M, et al: Sick leave for follow-up control in thyroid cancer patients: Comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 156:531-538, 2007
12. Mernagh P, Campbell S, Dietlein M, et al: Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. Eur J Endocrinol 155:405-414, 2006
13. Mernagh P, Suebwongpat A, Silverberg J, et al: Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective. Value Health 13:180-187, 2010
14. Wang TS, Cheung K, Mehta P, et al: To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab 95:1672-1680, 2010
15. Ramsey S, Willke R, Briggs A, et al: Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 8:521-533, 2005
16. Brazier J, Usherwood T, Harper R, et al: Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51:1115-1128, 1998
17. Lubitz CC, Kong CY, McMahon PM, et al: Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer 120:1345-1352, 2014
18. Revicki DA, Cella D, Hays RD, et al: Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 4:70, 2006
19. Chevalier J, de Pouvourville G: Valuing EQ-5D using time trade-off in France. Eur J Health Econ 14:57-66, 2013
20. Manca A, Hawkins N, Sculpher MJ: Estimating mean QALYs in trial-based cost-effectiveness analysis: The importance of controlling for baseline utility. Health Econ 14:487-496, 2005
21. Caisse Nationale d'Assurance Maladie et des Travailleurs Sociaux: Base des médicaments et informations tarifaires. http://www.codage.ext.cnamts.fr/codif/bdm// fiche/i
22. Koopmanschap MA, Rutten FF, van Ineveld BM, et al: The friction cost method for measuring indirect costs of disease. J Health Econ 14:171-189, 1995
23. Liljas B: How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13:1-7, 1998
24. Haute Autorité de Santé: Choix méthodologiques pour l'évaluation économique à la HAS. http://www.hassante. fr/portail/jcms/r-1499251/en/choices-in-methodsfor-economic-evaluation
25. Briggs AH: Handling uncertainty in costeffectiveness models. Pharmacoeconomics 17:479-500, 2000
26. Agency for Healthcare Research and Quality: US valuation of the EuroQol EQ-5 Health States. http:// www.ahrq.gov/professionals/clinicians-providers/ resources/rice/EQ5Dproj.html
27. National Institute for Health and Care Excellence: Guide to the methods of technology appraisal 2013, foreword: Guidance and guidelines. http:// www.nice.org.uk/article/PMG9/chapter/Foreword
28. Garau M, Shah KK, Mason AR, et al: Using QALYs in cancer: A review of the methodological limitations. Pharmacoeconomics 29:673-685, 2011
29. Rawlins MD, Culyer AJ: National Institute for Clinical Excellence and its value judgments. BMJ 329:224-227, 2004
30. Neumann PJ, Cohen JT, Weinstein MC: Updating cost-effectiveness: The curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371:796-797, 2014